Nutraceuticals and Drug Treatment in Frail Older Adults

Frailty Clinical Trial

Official title: Cognitive and Physical Impairment in Frail Older Adults

Status Recruiting

Clinical Trial Summary

Frailty is a multidimensional condition due to reserve loss leading to physical and cognitive impairment that is very common in older adults; in fact, its incidence increases with age. Frail older adults present a high risk of adverse events such as disability, hospitalization and mortality. It is very important to check comorbidities and complications to reduce the incidence of cognitive and physical impairment.

Clinical Trial Description

Frailty is a multidimensional condition due to reserve loss leading to physical and cognitive impairment that is very common in older adults; in fact, its incidence increases with age. Frail older adults present a high-risk of adverse events such as disability, hospitalization and mortality. It is very important to check comorbidities and complications to reduce the incidence of cognitive and physical impairment; hence, clinical evaluation is the main goal to get an early diagnosis and a timely treatment for cognitive impairment. Considering this background, the study will investigate the effects of nutraceuticals and drug treatment on cognitive impairment in frail older adults. In this scenario, global cognitive function will be evaluated with Mini Mental State Examination (MMSE) and Montreal Cognitive Assessment (MoCA) test and physical impairment with the Fried criteria and 5-metres gait speed test. ;

Related Conditions & MeSH terms

• Frailty

• NCT number: NCT04962841
• Study type: Observational
• Source: University of Campania "Luigi Vanvitelli"
• Contact: Pasquale Mone, MD
• Phone: 0823275386
• Email: pasquale.mone@unicampania.it
• Status: Recruiting
• Start date: April 1, 2020
• Completion date: April 1, 2023